Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
1.38
-0.01 (-0.36%)
Market open: Aug 12, 2026, 11:06 AM EDT
1.39
+0.01 (0.67%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
| Name | Position |
|---|---|
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, CEO & Chairman of the Board of Directors |
| Linda Moreira | Company Secretary |
| Mr. Jeffrey C. Himmelreich M.B.A. | Head of Finance and Principal Financial & Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-10 | 10-Q | form10-q.htm |
| 2026-05-22 | 8-K | form8-k.htm |
| 2026-05-19 | DEFA14A | formdefa14a.htm |
| 2026-05-14 | 8-K | form8-k.htm |
| 2026-05-11 | 10-Q | form10-q.htm |
| 2026-04-27 | DEFA14A | formdefa14a.htm |
| 2026-04-16 | 8-K | form8-k.htm |
| 2026-04-08 | 8-K | form8-k.htm |
| 2026-04-07 | S-8 | forms-8.htm |
| 2026-04-07 | DEFA14A | ny20065433x2_defa14a.htm |